ClinicalTrials.gg
RecruitingNCT06314204canhopeUpdated Mar 15, 2024

Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms

An observational study in Psychotic; Disorder, Cannabis, sponsored by Centre hospitalier de Ville-Evrard, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Centre hospitalier de Ville-Evrard, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2016; still recruiting 10 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

Few studies have evaluated, in patients with symptomatology the impact of cannabis use on the duration of hospitalization and on short- and medium-term developments. The objective of this study will be to assess the impact of cannabis on the duration, the hospitalization and the short- and medium-term evolution of patients with psychotic symptoms and cannabis use. We hypothesize that these patients (in comparison with patients with psychotic symptomatology and not using cannabis) would be hospitalized more long, exposed to a higher risk of resistance to the usual therapeutics, would have a lack of therapeutic alliance and insight, relapses and hospitalizations more frequent, more marked negative symptoms and lower quality remission. They would also be more prone to impulsive and aggressive behaviour.

Read the detailed description

Several studies have reported that cannabis use worsen the prognosis of psychiatric pathologies in general and psychotic in particular.

Few or no studies have evaluated the impact of cannabis consumption on patients with psychotic symptoms during their hospitalization (duration, type of hospitalization, quality of relationship with staff hospital), and on the short-term prognosis.

The objective of this study will be to assess the impact of cannabis on the duration of the hospitalization and the short- and medium-term evolution of patients with a psychotic symptomatology and cannabis use. Making the hypothesis that these patients (compared to patients with symptomatology psychotic and not using cannabis) would be hospitalized longer, exposed at a higher risk of resistance to the usual therapies, to have a lack of alliance therapeutic and insight, relapses and more frequent hospitalizations and symptoms.

They would also be more likely to have lower quality. They would also be more likely to be impulsive, and have aggressive behaviours.

02

Conditions studied

  • Psychotic; Disorder, Cannabis

Browse trials for

Keywords

  • cannabis-Timing-hospitalization-psychotic sympyomatology
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 200 is close to the median of 220 across 391 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Centre hospitalier de Ville-Evrard, France is the lead sponsor of 22 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population of this study will consist of patients over the age of 18 with trans-nosographic psychotic symptomatology (schizophrenia, schizoaffective disorder, mood disorder with psychotic characteristic, psychotic disorder induced by substances, brief psychotic disorder, schizophrenic disorder, delirious disorders), hospitalized in psychiatry, free care or under duress in the Hospitalization Units to Full-time (UHTP) EPS Ville-Evrard. This protocol also concerns protected adults. Forecasted number of patients: 200 patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized in psychiatry regardless of the mode of hospitalization
  • With or without protective measures (guardianship or curatorship)
  • Presenting psychotic symptoms (schizophrenia, schizo affective disorder, thymic disorder with psychotic characteristic, psychotic disorder substance-induced, brief psychotic disorder, schizophrenic disorders, delirious disorders)
  • Members of the social security system
  • Enlightened information

Exclusion criteria

Exclusion Criteria:

  • Degenerative neurological pathologies or mental retardation
  • Psychotic disorders secondary to generalized medical conditions(epilepsy, delirium tremens, tumors, etc.)
  • Other psychiatric pathologies
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. PANSS: Positive and Negative Syndrom Scale

    This scale permit to assess the severity of schizophrenia.Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales.

    Time frame: AT the beginning of the study, before any procedure, (T1)

  2. PANSS: Positive and Negative Syndrom Scale

    This scale permit to assess the severity of schizophrenia.Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales.

    Time frame: Approximatively 2 or 3 weeks after T1,On the day of the discharge (T2)

  3. PANSS: Positive and Negative Syndrom Scale

    This scale permit to assess the severity of schizophrenia.Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales.

    Time frame: 1 month after the discharge (T3)

  4. PANSS: Positive and Negative Syndrom Scale

    This scale permit to assess the severity of schizophrenia.Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales.

    Time frame: 3 month after the discharge (T4)

  5. MCQ-SF :Marijuana Craving Questionnaire- Short Form

    The scale permit to determine the marijuana craving. The subscales exhibited low to moderate, positive intercorrelations and were significantly correlated with marijuana use history and a wide range of single-item measures of craving. Conclusions. Findings suggested that four specific constructs characterize craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes.

    Time frame: AT the beginning of the study, before any procedure (T1)

  6. MCQ-SF :Marijuana Craving Questionnaire- Short Form)

    The scale permit to determine the marijuana craving. The subscales exhibited low to moderate, positive intercorrelations and were significantly correlated with marijuana use history and a wide range of single-item measures of craving. Conclusions. Findings suggested that four specific constructs characterize craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes.

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  7. MCQ-SF :Marijuana Craving Questionnaire- Short Form)

    The scale permit to determine the marijuana craving. The subscales exhibited low to moderate, positive intercorrelations and were significantly correlated with marijuana use history and a wide range of single-item measures of craving. Conclusions. Findings suggested that four specific constructs characterize craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes.

    Time frame: one month after the discharge

  8. MCQ-SF :Marijuana Craving Questionnaire- Short Form)

    The scale permit to determine the marijuana craving. The subscales exhibited low to moderate, positive intercorrelations and were significantly correlated with marijuana use history and a wide range of single-item measures of craving. Conclusions. Findings suggested that four specific constructs characterize craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes.

    Time frame: three month after the discharge

  9. CGI: Clinical Global Impression

    It is used with all patients, allowing the evaluation of the improvement of assessing the severity and change of the overall clinical condition. The clinical global impression - severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. 1. Normal, not at all ill 2. Borderline mentally ill 3. Mildly ill 4. Moderately ill 5. Markedly ill 6. Severely ill 7. Among the most extremely ill patients Improvement scale The clinical global impression - improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: AT the beginning of the study, before any procedure (T1)

  10. CGI: Clinical Global Impression

    It is used with all patients, allowing the evaluation of the improvement of assessing the severity and change of the overall clinical condition. The clinical global impression - severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. 1. Normal, not at all ill 2. Borderline mentally ill 3. Mildly ill 4. Moderately ill 5. Markedly ill 6. Severely ill 7. Among the most extremely ill patients Improvement scale The clinical global impression - improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  11. CGI: Clinical Global Impression

    It is used with all patients, allowing the evaluation of the improvement of assessing the severity and change of the overall clinical condition. The clinical global impression - severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. 1. Normal, not at all ill 2. Borderline mentally ill 3. Mildly ill 4. Moderately ill 5. Markedly ill 6. Severely ill 7. Among the most extremely ill patients Improvement scale The clinical global impression - improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: one month after the discharge

  12. CGI: Clinical Global Impression

    It is used with all patients, allowing the evaluation of the improvement of assessing the severity and change of the overall clinical condition. The clinical global impression - severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. 1. Normal, not at all ill 2. Borderline mentally ill 3. Mildly ill 4. Moderately ill 5. Markedly ill 6. Severely ill 7. Among the most extremely ill patients Improvement scale The clinical global impression - improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: three month after the discharge

  13. MADRS: Montgomery Åsberg Depression Rating Scale

    It is validated in France by Pellet and its collaborators in 1987. It allows to evaluate the modifications of mood. It has 10 psychic and somatic items (apparent sadness, sadness expressed, inner tension, insomnia, loss of appetite, difficulty concentrating, weariness, loss of feelings, pessimism and thoughts of suicide) sides from 0 to 6 according to the 6 degrees of severity and whose scores add up.

    Time frame: AT the beginning of the study, before any procedure (T1)

  14. MADRS: Montgomery Åsberg Depression Rating Scale

    It is validated in France by Pellet and its collaborators in 1987. It allows to evaluate the modifications of mood. It has 10 psychic and somatic items (apparent sadness, sadness expressed, inner tension, insomnia, loss of appetite, difficulty concentrating, weariness, loss of feelings, pessimism and thoughts of suicide) sides from 0 to 6 according to the 6 degrees of severity and whose scores add up.

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  15. MADRS: Montgomery Åsberg Depression Rating Scale

    It is validated in France by Pellet and its collaborators in 1987. It allows to evaluate the modifications of mood. It has 10 psychic and somatic items (apparent sadness, sadness expressed, inner tension, insomnia, loss of appetite, difficulty concentrating, weariness, loss of feelings, pessimism and thoughts of suicide) sides from 0 to 6 according to the 6 degrees of severity and whose scores add up.

    Time frame: one month after the discharge

  16. MADRS: Montgomery Åsberg Depression Rating Scale

    It is validated in France by Pellet and its collaborators in 1987. It allows to evaluate the modifications of mood. It has 10 psychic and somatic items (apparent sadness, sadness expressed, inner tension, insomnia, loss of appetite, difficulty concentrating, weariness, loss of feelings, pessimism and thoughts of suicide) sides from 0 to 6 according to the 6 degrees of severity and whose scores add up.

    Time frame: Three month after the discharge

  17. PDS: Psychotic Depression Scale

    It is composed of 32 items. Among the PDS items, those related to the "mood" factors depressive" (8 items) and "vegetative signs" (3 items) allow an evaluation of the depression regardless of negative symptoms or extrapyramidal symptoms. All items are scoring from 0 to 6: 0: nothing 2 :light 4: important 6: extreme

    Time frame: AT the beginning of the study, before any procedure (T1)

  18. PDS: Psychotic Depression Scale

    It is composed of 32 items. Among the PDS items, those related to the "mood" factors depressive" (8 items) and "vegetative signs" (3 items) allow an evaluation of the depression regardless of negative symptoms or extrapyramidal symptoms. All items are scoring from 0 to 6: 0: nothing 2 :light 4: important 6: extreme

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  19. PDS: Psychotic Depression Scale

    It is composed of 32 items. Among the PDS items, those related to the "mood" factors depressive" (8 items) and "vegetative signs" (3 items) allow an evaluation of the depression regardless of negative symptoms or extrapyramidal symptoms. The overall PDS score is correlated to the overall MADRS scores. All items are scoring from 0 to 6: 0: nothing 2 :light 4: important 6: extreme

    Time frame: one month after the discharge

  20. PDS: Psychotic Depression Scale

    It is composed of 32 items. Among the PDS items, those related to the "mood" factors depressive" (8 items) and "vegetative signs" (3 items) allow an evaluation of the depression regardless of negative symptoms or extrapyramidal symptoms. The overall PDS score is correlated to the overall MADRS scores. All items are scoring from 0 to 6: 0: nothing 2 :light 4: important 6: extreme

    Time frame: Three month after the discharge

  21. YMRS: Young Mania Rating Scale

    The YMRS is a scale of 11 questions to assess the severity of symptoms maniacs. It is considered the gold standard of scales evaluating mania. This instrument is widely used both in the clinic and in research. It is appropriate both to assess the initial severity of manic symptoms, and the response to treatment in patients with bipolar disorder type I and II. Each item of YMRS given a severity rating. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. There are well described anchor points for each grade of severity.

    Time frame: AT the beginning of the study, before any procedure (T1)

  22. YMRS: Young Mania Rating Scale

    The YMRS is a scale of 11 questions to assess the severity of symptoms maniacs. It is considered the gold standard of scales evaluating mania. This instrument is widely used both in the clinic and in research. It is appropriate both to assess the initial severity of manic symptoms, and the response to treatment in patients with bipolar disorder type I and II. Each item of YMRS given a severity rating. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. There are well described anchor points for each grade of severity.

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  23. YMRS: Young Mania Rating Scale

    The YMRS is a scale of 11 questions to assess the severity of symptoms maniacs. It is considered the gold standard of scales evaluating mania. This instrument is widely used both in the clinic and in research. It is appropriate both to assess the initial severity of manic symptoms, and the response to treatment in patients with bipolar disorder type I and II. Each item of YMRS given a severity rating. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. There are well described anchor points for each grade of severity.

    Time frame: one month after the discharge

  24. YMRS: Young Mania Rating Scale

    The YMRS is a scale of 11 questions to assess the severity of symptoms maniacs. It is considered the gold standard of scales evaluating mania. This instrument is widely used both in the clinic and in research. It is appropriate both to assess the initial severity of manic symptoms, and the response to treatment in patients with bipolar disorder type I and II. Each item of YMRS given a severity rating. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. There are well described anchor points for each grade of severity.

    Time frame: Three month after the discharge

  25. CDS: Self-Consciousness Revised Scale

    This scale represents a cross-cultural validation in of the Self-Consciousness Revised Scale by Scheier et al. This scale measures three aspects of the self-awareness, that is, private, public self-awareness and social anxiety. It includes 22 statements. The scale is rating 0-3 point: 0: not at all like me 1. a little bit like me 2. quite similar to me 3. Very much like me . The time to complete will be 10 minutes.

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  26. CTQ: Childhood Trauma Questionnaire

    The Child Trauma Questionnaire is a questionnaire developed by Bernstein et al. (1994) which includes 70 items with a scale of type Likert in five answer choices (from 1 = "never true" to 5 = "very often true"). It was developed from a detailed review of the literature on abuse and also from experience a structured interview, the Childhood Trauma Interview, developed by the same authors. The ten minutes will be required.

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

  27. BFI: Big Five Inventory

    The Personality Dimension Scale, BIG FIVE, FFS: John et al. developed the Big Five Inventory (BFI). This consists of 44 items in its American version, consisting of short phrases based on the adjectives of traits known to be the prototype markers of the "Big Five" John et al. no longer denotes the factors but assigns them a letter accompanied by a set of explanatory and synthetic terms of the definition: E (Extraversion, Energy, Enthusiasm); A (Agreeability, Altruism, Affection); C (Consciousness, Control, Constraint); N (Negative Emotions, Neuroticism, Nervousness); O (Openness, Originality, Openness). The Time of passing is 10 minutes. 1. disagree strongly 2. disagree a little 3. Neither agree or nor disagree 4. agree a little 5. agree strongly

    Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)

07

Study locations

1 of 1 sites recruiting
  • unité de recherche clinique de l'E.P.S de Ville Evrard
    Neuilly Sur Marne, 93332, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2016 (actual). Primary completion is estimated for Sep 2025, 107 months after the start.

Of 150 non-industry observational studies under Mental Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 77. This study's planned 107 months is above that.

Counting every sponsor, half of 157 studies reached it within 37 months; a quarter within 13 and three quarters within 77.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 15, 2024
StartActual
Sep 20, 2016
Primary completionEst.
Sep 6, 2025
CompletionEst.
Sep 6, 2026
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06314204
Lead sponsor
Centre hospitalier de Ville-Evrard, France
Responsible party
Noomane Bouaziz, MD (MBBS, psychiatrist and investigator, Centre hospitalier de Ville-Evrard, France) — Principal investigator
First posted
Mar 15, 2024
Start date
Sep 20, 2016
Primary completion
Sep 6, 2025 (estimated)
Completion
Sep 6, 2026 (estimated)
Last update
Mar 15, 2024

Study contacts

RUSHEENTHIRA THAVASEELAN, MSc
Contact
r.thavaseelan@epsve.fr
0143083232

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion